Apertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood Diseases
—Consortium led by the Broad Institute's Center for Therapeutic Genetics to use Apertura's novel CNS-targeted AAV capsid, TfR1 CapX™, for base and prime gene editing programs— NEW YORK, July 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation...
—Consortium led by the Broad Institute's Center for Therapeutic Genetics to use Apertura's novel CNS-targeted AAV capsid, TfR1 CapX™, for base and prime gene editing programs— NEW YORK, July 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.